3
views
0
recommends
+1 Recommend
2 collections
    0
    shares

      Call for Papers: Digital Diagnostic Techniques

      Submit here before November 30, 2024

      About Pathobiology: 3.5 Impact Factor I 8.5 CiteScore I 1.088 Scimago Journal & Country Rank (SJR)

      Call for Papers: Supportive Care - Essential for Modern Oncology

      Submit here before December 31, 2024

      About Oncology Research and Treatment: 2.0 Impact Factor I 3.2 CiteScore I 0.521 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Potential of Using qFibrosis Analysis to Predict Recurrent and Survival Outcome of Patients with Hepatocellular Carcinoma after Hepatic Resection

      other

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          There remains a lack of studies addressing the stromal background and fibrosis features and their prognostic value in liver cancer. qFibrosis can identify, quantify, and visualize the fibrosis features in biopsy samples. In this study, we aim to demonstrate the prognostic value of histological features by using qFibrosis analysis in liver cancer patients.

          Methods

          Liver specimens from 201 patients with hepatocellular carcinoma (HCC) who underwent curative resection were imaged and assessed using qFibrosis system and generated a total of 33 and 156 collagen parameters from tumor part and non-tumor liver tissue, respectively. We used these collagen parameters on patients to build two combined indexes, RFS index and OS index, in order to differentiate patients with early recurrence and early death, respectively. The models were validated using the leave-one-out method.

          Results

          Both combined indexes had significant prediction value for patients’ outcome. The RFS index of 0.52 well differentiates patients with early recurrence ( p < 0.001), and the OS index of 0.73 well differentiates patients with early death during follow-up ( p = 0.02).

          Conclusions

          Combined index calculated with qFibrosis from a digital readout of the fibrotic status of peri-tumor liver specimen in patients with HCC has prediction values for their disease and survival outcomes. These results demonstrated the potential to transform histopathological features into quantifiable data that could be used to correlate with clinical outcome.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: found

          Stromal gene expression predicts clinical outcome in breast cancer.

          Although it is increasingly evident that cancer is influenced by signals emanating from tumor stroma, little is known regarding how changes in stromal gene expression affect epithelial tumor progression. We used laser capture microdissection to compare gene expression profiles of tumor stroma from 53 primary breast tumors and derived signatures strongly associated with clinical outcome. We present a new stroma-derived prognostic predictor (SDPP) that stratifies disease outcome independently of standard clinical prognostic factors and published expression-based predictors. The SDPP predicts outcome in several published whole tumor-derived expression data sets, identifies poor-outcome individuals from multiple clinical subtypes, including lymph node-negative tumors, and shows increased accuracy with respect to previously published predictors, especially for HER2-positive tumors. Prognostic power increases substantially when the predictor is combined with existing outcome predictors. Genes represented in the SDPP reveal the strong prognostic capacity of differential immune responses as well as angiogenic and hypoxic responses, highlighting the importance of stromal biology in tumor progression.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Immunological hallmarks of stromal cells in the tumour microenvironment.

            A dynamic and mutualistic interaction between tumour cells and the surrounding stroma promotes the initiation, progression, metastasis and chemoresistance of solid tumours. Far less understood is the relationship between the stroma and tumour-infiltrating leukocytes; however, emerging evidence suggests that the stromal compartment can shape antitumour immunity and responsiveness to immunotherapy. Thus, there is growing interest in elucidating the immunomodulatory roles of the stroma that evolve within the tumour microenvironment. In this Review, we discuss the evidence that stromal determinants interact with leukocytes and influence antitumour immunity, with emphasis on the immunological attributes of stromal cells that may foster their protumorigenic function.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Fibroblasts in cancer.

              Tumours are known as wounds that do not heal - this implies that cells that are involved in angiogenesis and the response to injury, such as endothelial cells and fibroblasts, have a prominent role in the progression, growth and spread of cancers. Fibroblasts are associated with cancer cells at all stages of cancer progression, and their structural and functional contributions to this process are beginning to emerge. Their production of growth factors, chemokines and extracellular matrix facilitates the angiogenic recruitment of endothelial cells and pericytes. Fibroblasts are therefore a key determinant in the malignant progression of cancer and represent an important target for cancer therapies.
                Bookmark

                Author and article information

                Journal
                Oncology
                Oncology
                OCL
                OCL
                Oncology
                S. Karger AG (Basel, Switzerland )
                0030-2414
                1423-0232
                25 March 2024
                November 2024
                : 102
                : 11
                : 924-934
                Affiliations
                [a ]Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
                [b ]Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan
                [c ]Department of Traumatology, National Taiwan University Hospital, Taipei, Taiwan
                [d ]HistoIndex Pte Ltd, Singapore, Singapore
                [e ]Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan
                Author notes
                Correspondence to: Kai-Wen Huang, skywing@ 123456ntuh.gov.tw
                Article
                538456 00000
                10.1159/000538456
                11548100
                38527441
                e1749f4f-4f78-4514-b161-d9e81f2f9d4c
                © 2024 The Author(s). Published by S. Karger AG, Basel

                This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) ( http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.

                History
                : 8 January 2024
                : 27 February 2024
                : 2024
                Page count
                Figures: 5, Tables: 3, References: 26, Pages: 11
                Funding
                No funding was received in support of this work.
                Categories
                Clinical Study

                artificial intelligence,digital pathology,hepatocellular carcinoma,outcome,qfibrosis

                Comments

                Comment on this article